Next-generation sequencing
Comprehensive genetic testing to guide patient care
With numerous types of sarcomas that can have overlapping features, diagnosis can be challenging. Using only histological and immunophenotypic features can lead to a high rate of inaccurate diagnoses. Genetic testing can improve diagnostic accuracy and overall patient management.
Next-generation sequencing test menu
Next-generation sequencing panels
Mayo Clinic Laboratories’ comprehensive, next-generation sequencing sarcoma fusion panel includes 169 genes and assesses mutations and fusions described in more than 50 types of soft tissue, bone, and other mesenchymal tumors. Because fusion events can occur between known or novel gene partners, the panel is designed to provide the most comprehensive analysis by including 124 gene fusion pairs, 274 fusion variants, and novel gene partner detection.
Key testing
- MCSRC | MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumor
- Assists in establishing a definitive diagnosis of 50+ bone and soft tissue subtypes.
- Comprehensive panel evaluation of 169 genes for the presence of somatic gene mutations, fusions, and rearrangements.
- Robust fusion assessment can determine both known and novel fusion partners, which can be diagnostically important.
Additional testing
- MCSMP | MayoComplete Sarcoma Mutation Panel, Next-Generation Sequencing, Tumor
- Analyzes mutations in 31 genes.
- SARCP | Sarcoma Targeted Gene Fusion/Rearrangement Panel, Next-Generation Sequencing, Tumor
- Analyzes rearrangements for 138 genes.